Rockefeller Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-1,871
Closed -$2.13K – 4863
2026
Q2
$2.13K Hold
1,871
– – ﹤0.01% 4416
2026
Q1
$2.6K Hold
1,871
– – ﹤0.01% 4366
2025
Q4
$3.01K Hold
1,871
– – ﹤0.01% 4221
2025
Q3
$5.11K Buy
+1,871
New +$6.22K ﹤0.01% 3866
2023
Q1
– Sell
-3,771
Closed -$2K – 2021
2022
Q4
$2K Hold
3,771
– – ﹤0.01% 3532
2022
Q3
$1K Hold
3,771
– – ﹤0.01% 3661
2022
Q2
$1K Hold
3,771
– – ﹤0.01% 3893
2022
Q1
$2K Buy
3,771
+1,900
+102% +$4.06K ﹤0.01% 3574
2021
Q4
$4K Hold
1,871
– – ﹤0.01% 3323
2021
Q3
$5K Hold
1,871
– – ﹤0.01% 3152
2021
Q2
$7K Buy
+1,871
New +$6.3K ﹤0.01% 2903
2020
Q4
– Sell
-413
Closed -$1K – 2840
2020
Q3
$1K Buy
413
+157
+61% +$1.38K ﹤0.01% 2444
2020
Q2
$3K Sell
256
-167
-39% -$1.73K ﹤0.01% 2202
2020
Q1
$3K Buy
+423
New +$3.29K ﹤0.01% 2069

Other funds holding AKBA

Rockefeller Capital Management's AKBA Position: Q3 2026 in Review

Rockefeller Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 1,871 shares — an estimated $2.13K sold.

Rockefeller Capital Management first reported a position in AKBA in Q1 2020 and held it in 14 quarters. The position peaked at $7K in Q2 2021. 156 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Rockefeller Capital Management reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 1,871 Akebia Therapeutics shares in Q3 2026, an estimated $2.13K.
  • Rockefeller Capital Management first reported a position in Akebia Therapeutics in Q1 2020 and held it in 14 quarters.
  • Rockefeller Capital Management's Akebia Therapeutics position peaked at $7K in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.